Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Vetter announced the commissioning of a new warehouse designed to help meet increasing customer market supply demands. With a total investment of approx.
read more
Thursday, December 10, 2020
Fusion Antibodies and Queen’s University Belfast have been awarded a £453,000 grant from Invest Northern Ireland to further expand their COVID-19 targeted research and development efforts.
read more
Wednesday, September 20, 2023
Future Fields, a biotechnology company that has built the world’s first synthetic biology system to use fruit flies for recombinant protein production, announced the launch of its contract development and manufacturing organization (CDMO) service.
read more
G&W Laboratories has announced the appointment of Jay Galeotato the position of President and Chief Operating Officer. Mr. Galeota joins G&W following a 28-year career at Merck, where he was most recently Chief Strategy & Business Development Officer...
read more
Monday, December 23, 2019
G-CON Manufacturing announced the expansion of its manufacturing facility for POD superstructures in College Station, TX.
read more
G-CON Manufacturing announced the company will support Just – Evotec Biologics, a wholly-owned Seattle-based company of Evotec SE, with their construction of a late-stage clinical and commercial manufacturing facility for biologics in Redmond, ...
read more
Gaelic Laboratories, a GMP-approved manufacturer of beta-lactam antibiotics, has obtained BSI Kitemark Certification for Minimized Risk of Antimicrobial Resistance (AMR), recognizing its manufacturing practices aimed at limiting AMR development and ...
read more
Tuesday, January 07, 2025
Gaelic Laboratories has established a Commercial Arm in the UAE that enables the company to import, register, market and distribute medicines in the Middle East. With its newly opened Gaelic Drug Store LLC in Dubai, the company now has an ...
read more
Tuesday, December 16, 2025
Gaelic Laboratories announced its acquisition of Athlone Laboratories, a developer and manufacturer of oral dose Beta-Lactams, in a step that strengthens Gaelic’s market position, enhances manufacturing capabilities, and leverages supply chain ...
read more
Gaelic Laboratories and Athlone Laboratories have completed the first phase of their post-merger integration, aligning key systems and capabilities following their December 2025 horizontal acquisition that combined Ireland’s sole GMP-approved ...
read more
Monday, December 28, 2015
Galapagos NV and Gilead Sciences, Inc. have entered into a global partnership for the development and commercialization of the JAK1-selective inhibitor filgotinib for inflammatory disease indications.
read more
Tuesday, September 16, 2014
A distribution, license and supply agreement with Medical Developments International is now in place.
read more
Gallus BioPharmaceuticals, LLC (Gallus), a premier
pure-play biologics contract manufacturing organization (CMO) has signed a manufacturing
agreement with Symphogen, A/S (Symphogen), a private biopharmaceutical company developing
recombinant ...
read more
Wednesday, September 16, 2020
Gannex and Galmed have entered into a research agreement aiming at combination therapy of ASC41 and Aramchol for NASH.
read more
Wednesday, November 11, 2020
Galmed Pharmaceuticals and MyBiotics Pharma have entered into a research and development collaboration agreement to identify and optimize the selected microbiome repertoire associated with the response to Aramchol.
read more